Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION).  QPI-1007 exhibited no dose limiting toxicities up to and including the highest dose of 6 milligrams enabled in this study, which is the highest dose of synthetic siRNA tested in the clinic following intravitreal administration.  After 3 months of follow up, patients treated in the study by a single dose of QPI-1007 exhibited no further loss of visual acuity, whereas vision loss was observed in previous studies(1) in non-treated NAION patients with similar initial disease severity. With the exception of one patient whose vision remained stable, all patients exhibited letter gains compared to baseline at screening, with some patients gaining 3-lines or more by 3 months after treatment.

The ongoing Phase 1 open-label, dose-escalation study, which is being conducted in 22 sites in the USA and 6 sites in Israel, has enrolled a total of 38 patients in two strata: Stratum I was a dose-escalation safety study in patients who are legally blind secondary to chronic optic nerve atrophy or retinal degeneration and is fully enrolled; Stratum II was designed to further evaluate safety and to assess for potential biological activity of QPI-1007 in recent-onset NAION patients by monitoring changes in visual function  following drug administration.

In Stratum II, two cohorts of ten patients each were given a single intravitreal injection of one of two doses of QPI-1007. After one month of follow-up, 40% of patients in Cohort 1 and 60% of patients in Cohort 2 gained 3 or more lines of visual acuity. At
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2011 Express Scripts, Inc., one of the ... announced Rexam as its 2011 Supplier of the ... This award recognizes suppliers who have ... shown continuous improvement in supplier relationship management, quality, ...
... Ariz., Nov. 8, 2011 The Virginia G. Piper ... to accelerate advances in cancer care with the addition ... Angeles as a collaborator in clinical trials to develop ... treatments. The collaboration will focus on Phase ...
Cached Medicine Technology:Rexam Chosen as Express Scripts' Supplier of the Year 2Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai 2Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai 3Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai 4
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide ... Now, all of the models at LunaDress.co.uk come with big discounts, ... the wedding veil can turn out to be a most exciting ... veil can always bring surprise to a wedding. On the updated ... choose veils for a big day . , Going out ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... TUESDAY, June 14 (HealthDay News) -- For pregnant women, reducing ... on their left side, New Zealand researchers suggest. In ... left side had twice the risk of having a stillborn ... [from right-sided sleeping] is small for the individual," stressed lead ...
... June 15 (HealthDay News) -- Weight loss surgery patients who ... bypass have an increased risk of complications and death, a ... nearly 52,000 gastric bypass patients, researchers found that those released ... more likely to have serious complications (1.9 percent versus 0.16 ...
... , WEDNESDAY, June 15 (HealthDay News) -- Severely obese ... or become less frequent after having weight-reducing gastric bypass ... three years following surgery, 70 percent of the patients ... their migraines reduced from five to two a month, ...
... Africa Osteoporosis Meeting, to be held in Dubai, from ... , http://www.iofbonehealth.org/dubai-2011/programme.html To encourage participation by ... each for the top five abstracts by investigators up ... June 17, 2011; all accepted abstracts will be published ...
... 23andMe, a leading personal genetics company, announced that it has ... information. In the three and a half years since ... has grown to include the DNA data of more than ... for insights into their health and ancestry, more than three-fourths ...
... 2011, the New York Academy of Sciences will ... molecular biologists and patient advocates to discuss current ... and management of the cognitive symptoms of MS. ... Dysfunction in Multiple Sclerosis: New Approaches to Diagnosis ...
Cached Medicine News:Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 3Health News:Rushed Discharge After Weight-Loss Surgery May Raise Risks 2Health News:For Many, Weight-Loss Surgery Also Eases Migraines 2Health News:For Many, Weight-Loss Surgery Also Eases Migraines 3Health News:Program announced for 1st Middle-East & Africa Osteoporosis Meeting 2Health News:23andMe database surpasses 100,000 users 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
... Series 1000 Power Instrument System is a ... and convenience with modular and unitized handpieces., ... for use with 1025 Power Console. Accepts ... Also available without hand throttle (#1000E) for ...
... Micro Drill, without hand throttle, ... torque. Built-in medium bur guard ... (#1100-006) bur guards are also ... foot throttle (#6401-000), can also ...
Medicine Products: